Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 13/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | AKT2 | P31751 | 2/20 | 0.41 |
| ▸ | AKT3 | Q9Y243 | 2/20 | 0.41 |
| ▸ | CIT | O14578 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.41 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3332387 | 0.90 | ROCK2 (0.44) | MAPK1ROCK1ROCK2PRKACAPIN1 | |
| SCHEMBL3330630 | 0.85 | ROCK1 (0.52) | MAPK1ROCK1AKT1AKT2AKT3 | |
| SCHEMBL3329927 | 0.82 | MEN1 (0.37) | MAPK1 | |
| SCHEMBL1529840 | 0.78 | MAPK1 (0.40) | MAPK1ROCK1AKT1AKT2AKT3 | |
| SCHEMBL1539555 | 0.77 | AKT1 (0.46) | MAPK1ROCK1AKT1AKT2AKT3 | |
| SCHEMBL28559335 | 0.77 | ROCK1 (0.37) | ROCK1AKT1AKT2AKT3CIT | |
| SCHEMBL28559331 | 0.77 | ROCK1 (0.37) | ROCK1AKT1AKT2AKT3CIT | |
| SCHEMBL2636369 | 0.76 | PIN1 (0.43) | MAPK1PIN1 | |
| SCHEMBL10324428 | 0.76 | PIN1 (0.46) | ROCK1AKT1AKT2AKT3CIT | |
| SCHEMBL10447826 | 0.76 | PIN1 (0.46) | ROCK1AKT1AKT2AKT3CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338434-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-12-25 | — | — | US | disclosed |
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137338-A1 | INHIBITORS OF Akt ACTIVITY | PI4KB, AKT3, AKT2 | MAPK1 80/4885ROCK1 414/4885AKT1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.